All News
Rheumatology: Believe It or Not (4/25/2025)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Should we believe the reviews and metanalyses?
Read ArticleSenescent "Zombie" Cells and Low Back Pain
In a preclinical study led by McGill University researchers, two drugs targeting “zombie cells” have been shown to treat the underlying cause of chronic low back pain.
Read ArticleGenomics and Future Drug Targets for Osteoarthritis
A Nature article details the results of an osteoarthritis, genome-wide association study meta-analyses across up to 489,975 cases and 1,472,094 controls, establishing 962 independent associations, 513 of which have not been previously reported.
Read ArticleEMR Messaging Woes (4.11.2025)
Dr. Jack Cush reviews the news, journal reports and regulatory approvals from this past week on RheumNow.com
Read ArticleACP: Best Practice Advice on Cannabis or Cannabinoids Use for Chronic Noncancer Pain
The American College of Physicians published a best practice advisory on cannabis or cannabinoids in the Annals of Internal Medicine.
Read ArticleMindfulness and CBT improve chronic low back pain
Behavioral interventions were associated with reduced pain and daily opioid use and improved function and quality of life for up to 12 months among adults with opioid-treated chronic low back pain, according to a new randomized clinical trial.
Read ArticleConsensus Against Interventional Injections for Chronic Spinal Pain
BMJ has published a clinical practice guideline resulting from the work of an international, multidisciplinary panel addressing chronic spine pain (≥3 months duration) not associated with cancer or inflammatory arthropathy.
Cancer Survival with TNF Inhibitors (3.28.2025)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com
Read ArticleRepetitive Transcranial Magnetic Stimulation in Fibromyalgia
A randomized, sham-controlled trial has shown that repetitive transcranial magnetic stimulation (rTMS) reduced pain in fibromyalgia for up to 8 weeks; while analgesic effects waned, functional improvements remained during extended maintenance at week 16.
Read Article


